Guardant Health rises as FDA clears blood test for lung cancer drug use

Guardant Health

11/06/2026 13:26

** Shares of medical diagnostics company Guardant Health GH.O rise 2% to $133.23 premarket 
** Co says FDA approves Guardant360 CDx to detect HER2 gene mutations in advanced lung cancer, a common and serious form of the disease
** Says the blood test helps identify patients eligible for Boehringer Ingelheim's Hernexeos, first targeted therapy for this subgroup
** Says test uses blood sample instead of tissue biopsy, offering quicker and less invasive detection
** Co says this marks 27th approval of Guardant360 CDx as a companion diagnostic across cancers
** Says tests are covered by Medicare and most U.S. insurers
** As of last close, stock up ~18% YTD

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))